HLB liver cancer drug approved in the US again... U.S. FDA “Requests to supplement manufacturing facilities”
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Park Sang-hyun = The U.S.
(Seoul = Yonhap News) Reporter Park Sang-hyun = The U.S. product approval for the liver cancer drug 'rivoceranib' promoted by HLB [028300] was once again rejected.
← Back